1 May 2026Injectable drugsSource update: June 2025
Artesunate injectable
Two-step injectable artesunate guidance for severe malaria and initial treatment when oral therapy is not possible.
Prescription under medical supervision
This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.
Therapeutic action
Antimalarial.
Indications
- Treatment of severe malaria.
- Initial treatment of uncomplicated malaria, when persistent vomiting precludes oral therapy.
Forms and strengths, route of administration
- Powder for injection (artesunate), 60 mg vial, plus solvent: 5% sodium bicarbonate 1 ml ampoule, plus diluent: 0.9% sodium chloride 5 ml ampoule.
- For reconstitution, add the sodium bicarbonate into the vial and shake gently until clear.
- For slow IV, add 5 ml of 0.9% sodium chloride into the vial to obtain 10 mg/ml.
- For slow IM, add 2 ml of 0.9% sodium chloride into the vial to obtain 20 mg/ml.
- Never administer by IV infusion.
Dose and duration
One dose on admission, then 12 hours after admission, then 24 hours after admission, then once daily.
Administer for at least 24 hours, minimum 3 doses, then if the patient can tolerate the oral route, change to a full 3-day course of an artemisinin-based combination.
- Child under 6 kg: seek specialist advice.
- Child 6 kg to under 20 kg: 3 mg/kg per dose.
- Child 20 kg and over and adult: 2.4 mg/kg per dose.
- If the patient still cannot tolerate the oral route, continue one daily parenteral dose until oral therapy is possible, not exceeding 7 days of parenteral treatment.
| Weight | Dose per injection (mg) | Artesunate 10 mg/ml solution for IV Dose per injection (ml) | Artesunate 20 mg/ml solution for IM Dose per injection (ml) |
|---|---|---|---|
| Child 6 to < 20 kg | |||
| 6 to < 7 kg | 20 mg | 2 ml | 1 ml |
| 7 to < 11 kg | 30 mg | 3 ml | 2 ml |
| 11 to < 14 kg | 40 mg | 4 ml | 2 ml |
| 14 to < 17 kg | 50 mg | 5 ml | 3 ml |
| 17 to < 20 kg | 60 mg | 6 ml | 3 ml |
| Child ≥ 20 kg and adult | |||
| 20 to < 26 kg | 60 mg | 6 ml | 3 ml |
| (a) 26 to < 30 kg | 70 mg | 7 ml | 4 ml |
| 30 to < 34 kg | 80 mg | 8 ml | 4 ml |
| 34 to < 38 kg | 90 mg | 9 ml | 5 ml |
| 38 to < 42 kg | 100 mg | 10 ml | 5 ml |
| 42 to < 46 kg | 110 mg | 11 ml | 6 ml |
| 46 to < 51 kg | 120 mg | 12 ml | 6 ml |
| (a) 51 to < 55 kg | 130 mg | 13 ml | 7 ml |
| 55 to < 59 kg | 150 mg | 14 ml | 7 ml |
| 59 to < 63 kg | 150 mg | 15 ml | 8 ml |
| 63 to < 67 kg | 160 mg | 16 ml | 8 ml |
| 71 to < 76 kg | 180 mg | 18 ml | 9 ml |
|---|---|---|---|
| (a) 76 to < 80 kg | 190 mg | 19 ml | 10 ml |
| 80 to < 84 kg | 200 mg | 20 ml | 10 ml |
| 84 to < 88 kg | 210 mg | 21 ml | 11 ml |
Contra-indications, adverse effects, precautions
- Once reconstituted, the solution must be used immediately.
- May cause gastrointestinal disturbances, dizziness, headache, fever, muscle and joint pain, pruritus, and rarely rash or delayed haemolytic anaemia.
- Pregnancy and breast-feeding: no contra-indication.
- The solution should be clear; do not use if cloudy or if a precipitate is present.
- The 2-step and 1-step artesunate 60 mg formulations are bioequivalent and can be used interchangeably during the course of treatment, but use only the solvent or diluent provided by the manufacturer for each formulation.
Source
MSF Essential drugs practical guidelines (January 2026)
This page reproduces the structured reference information for this batch while leaving out the Storage and Remarks sections.
Rate this guide
Be the first to rate this guide.